Literature DB >> 16932426

Primary aldosteronism: diagnostic and treatment strategies.

Cecilia Mattsson1, William F Young.   

Abstract

Primary aldosteronism is caused by bilateral idiopathic hyperplasia in approximately two-thirds of cases and aldosterone-producing adenoma in one-third. Most patients with primary aldosteronism are normokalemic. In the clinical setting of normokalemic hypertension, patients who have resistant hypertension and hypertensive patients with a family history atypical for polygenic hypertension should be tested for primary aldosteronism. The ratio of plasma aldosterone concentration to plasma renin activity has been generally accepted as a first-line case-finding test. If a patient has an increased ratio, autonomous aldosterone production must be confirmed with an aldosterone suppression test. Once primary aldosteronism is confirmed, the subtype needs to be determined to guide treatment. The initial test in subtype evaluation is CT imaging of the adrenal glands. If surgical treatment is considered, adrenal vein sampling is the most accurate method for distinguishing between unilateral and bilateral adrenal aldosterone production. Optimal treatment for aldosterone-producing adenoma or unilateral hyperplasia is unilateral laparoscopic adrenalectomy. The idiopathic bilateral hyperplasia and glucocorticoid-remediable aldosteronism subtypes should be treated pharmacologically. All patients treated pharmacologically should receive a mineralocorticoid receptor antagonist, a drug type that has been shown to block the toxic effects of aldosterone on nonepithelial tissues.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16932426     DOI: 10.1038/ncpneph0151

Source DB:  PubMed          Journal:  Nat Clin Pract Nephrol        ISSN: 1745-8323


  61 in total

1.  [A 58-year-old hypertensive patient with primary hyperaldosteronism and renal artery stenosis].

Authors:  Michael Nguyen Quang; Bernd Krüger; Christopher D Krüger; Andreas Walberer; Bernhard Schenck; Klaus Kisters; Martin Wenning; Bernhard K Krämer
Journal:  Med Klin (Munich)       Date:  2010-04

2.  46-year-old man with treatment-resistant hypertension.

Authors:  Nicholas M Orme; Phil A Hart; Karen F Mauck
Journal:  Mayo Clin Proc       Date:  2010-10       Impact factor: 7.616

3.  Severity of obstructive sleep apnea is related to aldosterone status in subjects with resistant hypertension.

Authors:  Carolina C Gonzaga; Krishna K Gaddam; Mustafa I Ahmed; Eduardo Pimenta; S Justin Thomas; Susan M Harding; Suzanne Oparil; Stacey S Cofield; David A Calhoun
Journal:  J Clin Sleep Med       Date:  2010-08-15       Impact factor: 4.062

4.  11C-metomidate positron emission tomography after dexamethasone suppression for detection of small adrenocortical adenomas in primary aldosteronism.

Authors:  J Hennings; A Sundin; A Hägg; P Hellman
Journal:  Langenbecks Arch Surg       Date:  2010-07-20       Impact factor: 3.445

Review 5.  Resistant hypertension and aldosteronism.

Authors:  Eduardo Pimenta; David A Calhoun
Journal:  Curr Hypertens Rep       Date:  2007-11       Impact factor: 5.369

Review 6.  Aldosterone in the brain.

Authors:  Joel C Geerling; Arthur D Loewy
Journal:  Am J Physiol Renal Physiol       Date:  2009-03-04

Review 7.  Primary aldosteronism: A contrarian view.

Authors:  Norman M Kaplan
Journal:  Rev Endocr Metab Disord       Date:  2011-03       Impact factor: 6.514

8.  Primary aldosteronism associated with a germline variant in CACNA1H.

Authors:  Kendra Wulczyn; Edward Perez-Reyes; Robert L Nussbaum; Meyeon Park
Journal:  BMJ Case Rep       Date:  2019-05-23

9.  Predictors of malignancy in primary aldosteronism.

Authors:  Ayman Agha; Matthias Hornung; Igors Iesalnieks; Andreas Schreyer; Ernst Michael Jung; Assad Haneya; Hans J Schlitt
Journal:  Langenbecks Arch Surg       Date:  2013-09-19       Impact factor: 3.445

Review 10.  Resistant hypertension and hyperaldosteronism.

Authors:  Carolina C Gonzaga; David A Calhoun
Journal:  Curr Hypertens Rep       Date:  2008-12       Impact factor: 5.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.